Please note: In October and November 2010, the MHRA moved from its Market Towers address to a new location on Buckingham Palace Road. Please go to the contact us section of the website for updated contact details.
Safety of venlafaxine in children and adolescents under 18 years in the treatment of depressive illness - message from Professor G Duff, Chairman of the Committee on Safety of Medicines
New results from clinical trials in children and adolescents have been reviewed by the CSM's Expert Working Group on SSRIs. The trials did not demonstrate efficacy in depressive illness in this age group (6-17) and showed an increase in the rate of harmful outcomes including hostility, suicidal ideation and self-harm in the venlafaxine (Efexor, Efexor XL) group compared with the placebo group.
